Experimental Bruton’s tyrosine kinase (BTK) inhibitors, such as tolebrutinib or evobrutinib, are as effective as the approved therapy Aubagio (teriflunomide) at preventing relapses in people with relapsing forms of multiple sclerosis (MS), according to a review of published studies. The review found the therapies to be equally safe. BTK inhibitors are better at delaying short-term…
Category: Multiple Sclerosis Research
Warning signs of multiple sclerosis may surface years before diagnosis
Years before a diagnosis of multiple sclerosis (MS), people who later develop the disease have more doctor visits and hospitalizations for sensory, nervous system, and muscle problems than people in the general population, according to a recent study. The findings support the idea of an early phase of MS, known as the prodromal phase, when…
Time for me to Eat SH1?
Tweet Here we a have a case report of a lady who has tried a number of disease modifying treatments which were all discountinued due to lack of effect and side effects. They had been drug free for a decade and no MRI lesions but had longstanding gastrointestinal problems including smelly boffs, cramps and continence…
Shana Stern – MSAA’s February 2026 Artist of the Month
MSAA features the work of many talented artists affected by multiple sclerosis as part of our annual MSAA Art Showcase. Each month we share these artists’ inspiring stories and beautiful artwork with you as our Artist of the Month. This month, we celebrate Shana Stern as February’s … Continue reading → Source: blog.mymsaa.org
For young nonsmokers, following Mediterranean diet may slash MS risk
Closely following a Mediterranean diet — which involves eating lots of fruits, vegetables, and whole grains, and limiting intake of processed and sugary foods — is associated with a significantly lower risk of developing multiple sclerosis (MS), a large Swedish study has found. The benefits, however, were seen mostly among nonsmokers and people younger than…
Imaging Hot Microglia?
Tweet We all want to monitor progression and many years ago it was suggested that TSPO is a marker of activated microglia and we have a large number of imaging studies claiming that using TSPO imaging we can see activated microglia in MS. We however we published this paper. Nutma E, Fancy N, Weinert M,…
anti-CD20 saving alemtuzumab failure
Tweet Bruno PA, Barone S, Pascarella A, Lanza PL, Tinelli E, Gambardella A, Valentino P. B-cell-driven relapse and anti-CD20 rescue therapy after Alemtuzumab in RRMS: case report and literature review. Front Immunol. 2026;16:1710669. Background: Alemtuzumab is an immune reconstitution therapy (IRT) approved for highly active relapsing-remitting multiple sclerosis (RRMS). Notably, the differential reconstitution of B and…
Dan’s healing: The weeks after surgery
Today marks nine days since Dan’s hernia surgery. From my perspective, he is healing like a champ. Each day he is a little steadier, a little stronger, and a little more himself. His pain is easing and watching his body recover has been a genuine relief. And still, this week has been about more than…
The switching option after fingolimod?
Tweet Yesterday we had CD20-depleting antibodies switch after alemtuzumab works well and today it is a switch from fingolimod. Fingolimod is a strange drug because it hangs around a long time and when the drug wears of there is the potential for relapse = rebound Now it have been suggested that relapse occurs more frequently…